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Acronyms:
CBP  Chronic Back Pain
CCK   Cholecystokinin 
CR    Conditioned Response
CS    Conditioned Stimulus/Stimuli 
NSAID   Nonsteroidal Anti-Inflammatory Drug
PAG  Periaqueductal Gray 
UCR  Unconditioned Response
UCS   Unconditioned Stimulus/Stimuli
Introduction
Since the 18th century, people have believed that placebo pills 
were inert drugs or medically unqualified measures that have 
psychological effects on the patient, therefore easing the pa-
tient’s pain (Beecher 1955). Hence, the term placebo is a Latin 
derivative for “I shall please” (Moerman 2002). Furthermore, in 
recent years, many studies are associating neurological aspects 
to the psychological effects of the placebo effect. 
Today there is a range of treatment that people categorize as 
placebo - as basic as administering a Band-Aid on a wound to 
inserting needles into a patient receiving acupuncture. Because 
such procedures do not contain much medical efficiency, their 
pain-reducing results are termed ‘placebo effect.’ If these prac-
tices do not involve elements or substances that are responsi-
ble for altering a health condition then what is it about these 
techniques that can make one pain free? Because placebo an-
algesia has proven to be one of the most successful models in 
the research of the placebo effect, this review will explain the 
long-known psychological influences of the placebo analgesia, as 
well as the newer and unconcluded neurological influences of 
the placebo analgesia. 
Several psychological mechanisms contribute to the appear-
ance, enhancement or duration of the placebo effects. Firstly, 
Pavlov’s classical conditioning is a major contributor towards 
the placebo effect, whereby a patient is trained to respond pos-
itively towards a placebo stimulus.  Expectations also play a big 
role - the patient’s anticipation of clinical improvement is par-
tially responsible for the onset of the placebo effect. The overall 
experience that the patient experiences influences the patient’s 
expectations; doctor-patient relationship, the trial site, the ap-
pearance of the pill, and the way the treatment is given are all 
experience related factors that impact one’s expectations. 
How can it be that just by one merely having belief one can 
experience less or no pain? The neural mechanisms whereby 
placebo conditioning leads to placebo analgesia remain unclear. 
Scientists are attempting to find better explanations for the 
placebo effect by attributing it to neurological mechanisms of 
the body. Ascending pain signals travel through one’s spinal cord, 
then to the thalamus, and then to the sensory- processing re-
gions of one’s cerebral cortex. In order for one not to experi-
ence pain due do to a pain provoking stimulus, there would have 
to be changes in the sensory network of the brain or in the spi-
nal cord. Recently, researchers are associating opiate analgesics 
to the placebo effect. They are attempting to prove that placebo 
treatment engages opioid systems which block pain in the spinal 
cord. However, studies also show that there in fact is non-opioid 
related analgesia. Nonetheless, the explanations remain unclear. 
From the research done, it is evident that the placebo effect has 
psychological aspects and that there is a difference in brain ac-
tivity due to placebo treatment which is seemingly responsible 
for placebo analgesia. Nonetheless, future research is required 
in order to pinpoint the definite neural activity responsible for 
the pain reduction.
Methods
In an effort to answer the question asked above, many published 
articles, clinical trials, and research papers have been examined. 
Primarily, Touro College’s library database as well as Google 
Scholar were used to search for pertinent material. Original 
research papers that were referenced were also studied. An 
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attempt was made to determine if the placebo effect, as a result 
of the placebo treatment, is psychologically and or neurological-
ly fact or fiction.
Discussion
Psychological Aspects: Learning and Classical 
Conditioning
People who suffer from pain, like a headache, and who usually 
ingest aspirin, learn to associate the color, taste, and shape of 
the pill with pain-decrease. After recurring associations, if such 
people are given a placebo pill, such as a sugar pill resembling as-
pirin, they will feel less pain. Other stimuli, such as medical per-
sonnel features, hospitals, and therapeutic equipment can also 
be associated with clinical improvements and therefore act as 
conditioned stimuli that impact healing effects (Benedetti, et. al. 
2010). A 1960s’ experiment found that a scopolamine injection, 
a medication used to treat motion sickness and other types of 
nausea, affected motor changes in a rat. Furthermore, identical 
motor changes also transpired after a placebo injection made 
of saline solution was administered after the scopolamine in-
jection (Herrnstein 1962). Corresponding occurrences exist in 
humans too. Notably, if a placebo pill or procedure is given after 
two preceding administrations of an effective painkiller or prac-
tice, the placebo analgesic response is much larger (Amanzio, 
Benedetti, 1999). That effect emphasizes that the placebo effect 
is definitely a learning phenomenon.
Like other profound scientific developments, classical condition-
ing was discovered accidentally. In the 1890s, Russian physiolo-
gist Ivan Pavlov was observing dogs salivate in response to being 
fed. He then noticed that the dogs began salivating whenever 
he arrived in the room they were in, while he did not always 
have food with him (McLeod 2007). From this incident, Pavlov 
believed that some responses are innate, they don’t need to 
be learned. In example, dogs do not learn to salivate whenever 
they see food as this reflex is inherent. In psychological terms, 
an unconditioned stimulus leads to an unconditioned response. 
Furthermore, over time the dogs began salivating as soon as they 
saw anything that they associated with their food. Therefore, 
they would salivate in the presence of a lab assistant even when 
he did not come with food (Windholz 1995). In psychological 
terms, the phenomenon is due because when an unconditioned 
stimulus is paired with a neutral stimulus, the latter becomes a 
conditioned stimulus that propels a conditioned response com-
parable to the unconditioned response. Pavlov furthered his 
research by experimenting with a bell; the dog was conditioned 
to salivate when a bell rang as he associated it with the food.
Numerous clinical trials attribute the positive placebo treat-
ment effects to Pavlov’s classical conditioning. Just as a dog sali-
vated in response to a food-associated person or object, people 
can experience a reduction in pain due to a painkiller-associated 
placebo procedure or drug. Indeed, a 1970s’ experiment proves 
that placebo effects are in large due to classical conditioning; 
saccharin, a flavored drinking solution, was paired with cyclo-
phosphamide, an immunosuppressive drug, and given to rats. 
After, the rats were immunized with sheep red blood cells. 
On the seventh day, the rats that had been again exposed to 
saccharin at the time of antigenic stimulation had a lower con-
centration of hemagglutinating antibodies in comparison with 
non-conditioned animals given saccharin, conditioned animals 
that were not re-exposed to saccharin, and a placebo group. 
Hence, the experiment proves that after associative learning, 
simply a liquid has the ability to mimic the effects of an active 
drug and thus legitimizes the placebo effect (Ader, Cohen 1975). 
In response to people who argue that such conditioning is 
not possible to exist amongst human beings, an analogous trial 
provides substantial evidence that behavioral conditioning of 
immunosuppression is in fact promising in humans. Recurrent 
associations between cyclosporine A - an immunosuppressant 
drug - and a flavored drink incited conditioned immunosup-
pression in healthy male volunteers. However, more than one 
associative learning trial was necessary in order to bring about 
the fascinating results (Goebel, et al 2002).
Psychological Aspects: Expectancy
While Pavlovian conditioning serves as an unconscious influ-
ence towards placebo effects, expectancy serves as a conscious 
one. The expectancy theory hypothesizes that one’s expecta-
tions impact ones future experience (Kirsch 1999). Therefore, if 
one expects clinical improvement, his chances of improving are 
that much greater. This theory is evident in the following 2010 
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double-blind clinical trial: A painful laser stimulus was delivered 
individually to twenty healthy participants before and after each 
was given a 0 or 4 mg/kg cup of caffeine. Some participants were 
told that their drink contained a painkiller, while the others 
were told their drink was a placebo solution. After measuring 
the reported pain and expectancy levels, it was clear that the 
information that a painkiller was given enhanced the analgesic 
effect of caffeine compared to caffeine given with no drug infor-
mation (Bjørkedal, Flaten 2011). Moreover, those that were in 
the active placebo condition group - were told they were given 
a painkiller and they received caffeine – overall reported less 
pain than the subjects in the caffeine condition group – were 
not told they were given painkiller and they received caffeine. 
This reiterates the expectancy theory, as the first group was 
given two qualities (caffeine and drug information) that made 
them expect an improvement, while the latter group was only 
given one (caffeine).The expectancy of pain relief modulated the 
decreased pain experienced by the subjects (fig. 2).  
From the above trial, it is evident that verbal gestures enhance 
expectancy in patients. Additionally, the overall experience 
that the patient experiences influences his/her expectancy of 
clinical improvement and consequently his/her clinical results. 
The doctor-patient relationship, the trial site, the appearance 
of the pill, and the way the treatment is given are all includ-
ed in one’s experience and can enhance the placebo effect.  In 
another study, the effectiveness of 5% Lidocaine patches was 
compared with the effectiveness of placebo patches in treating 
chronic back pain. In the randomized double-blind study, 15 pa-
tients received 5% Lidocaine patches and 15 received placebo 
patches. Functional MRI was used to ascertain brain activity for 
variations of spontaneous pain, at the starting time and at two 
more points thereafter (6 hours and 2 weeks). As reported, 
there was no noteworthy difference between the two groups 
in their pain intensity and in pain related brain activity. And both 
groups reported more than a 50% pain decrease. Moreover, 
when compared with an untreated chronic-back-pain-group at 
similar intervals, the patch treated CBP group experienced a 
considerably bigger decrease in back pain (Hashmi et al, 2012). 
These findings support the expectancy theory, as the patients 
who experienced a more encouraging experience by being 
given a patch consequently felt less pain later on (fig. 3). 
Another method to reinforce one’s expectation of clinical 
improvement, is to educate the individual about the so-called 
painkiller one is going to ingest. A random group of fifty uni-
versity students agreed to either undergo placebo treatment 
under the appearance of a new analgesic painkiller capsule or 
to be put in the control group which did not receive placebo 
treatment. While some participants were handed educational 
handouts explaining the analgesic effect, others were not. The 
subjects then received electrically-induced pain at varied inten-
sities, and those that ingested the realistic looking drug capsules 
reported analgesia. Furthermore, participants who also read the 
handouts regarding analgesia reported an even higher decrease 
in pain (Tang, Colagiuri 2013). This experiment highlights that 
the appearance of the pill and the knowledge of analgesia both 
contribute towards the patients expectancy and thus towards 
his or her placebo analgesia. 
Psychological Aspects: Conditioning vs. 
Expectancy Theory
After much research, it is evident that both the conditioning 
and expectancy theories are driving forces of placebo effects. 
Subjects reported larger reductions in pain after 4mg/kg caffeine 
(caffeine, active placebo) compared to after 0mg caffeine (control, 
placebo)  (Bjørkedal, Flaten 2011)
Figure 2
Variation of CBP pain with treatment type and treatment duration. 
Treatment duration, but not type, significantly decreased CBP pain. 
(Hashmi et al) 
Figure 3
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However, can they coexist, and is one more potent than the 
other? In response to the former, both psychological mecha-
nisms can surely coincide. For example, a patient who receives 
a sugar pill on its own after repetitively receiving the pill togeth-
er with other analgesic drugs will imply both mechanisms; the 
sugar pill has become the conditioned stimulus to invoke anal-
gesia, and the fact that the patient received medicine prompts 
him to expect a recovery. 
Regarding which mechanism is more vital, Stewart-Williams 
and Podd (2004) reviewed many clinical trials and concluded 
similarly to what many others have suggested: each mechanism 
plays a different part in the production of placebo effects. When 
a doctor verbally encourages a patient, when an inert pill or 
procedure resembles a legitimate pill or procedure, and when 
other such characteristics mentioned previously exist when 
a patient receives a placebo, he/she learns to expect an im-
provement, which is a conscious belief. When one’s conscious 
is involved, he can experience subjective and or physiological 
placebo effects. On the other hand, when placebos represent 
CS, the patient can either unconsciously believe in a placebo 
effect or the patient can consciously expect improvements in 
his situation. The conscious expectations and the non-conscious 
learning yields subjective and physiological (objective) placebo 
effects. Whilst expectancy learning is always a conscious action, 
conditioning can be conscious or not - depending on whether 
expectancy coincides with the conditioning. Nonetheless, each 
form of learning can produce subjective as well as physiological 
outcomes.  
Others describe the correlation between expectations and 
conditioning differently. A study concluded that placebo re-
sponses are facilitated by expectation when conscious physi-
ological processes - for example, pain - exist, notwithstanding, 
a conditioning procedure may simultaneously be implemented 
(Benedetti et. al, 2003). Sixty participants were divided into five 
groups and induced with pain in their forearms once per day 
for five days. Such ischemic pain increases over time rapidly, and 
the pain becomes excruciating after approximately 13 minutes. 
After the painful stimulus was implied, each participant stopped 
a timer when the pain became unbearable, and thus the average 
pain tolerance level for each group was recorded. As each group 
was treated differently throughout the five days, the results of 
each group greatly varied. Some were told analgesia suggestions 
or hyperalgesia suggestion, some experienced conditioining 
via ketorolac anti inflamatory analgesic, and some received a 
combination. Evidently, verbally induced analgesia expectations 
raised the pain tolerance; whereas, suggestions of hyperalgesia 
eradicated pain tolerance. This testifies that not only are pos-
itive words empowering, negativity is impactful too. Moreover, 
this highlights the detrimental effects of unencouraging words 
in the medical scene. When analgesia suggestions and condition-
ing were both implemented, the tolerance level rose higher. Yet, 
when conditioning and hyperalgesia suggestions coincided, the 
expectations outweighed the preconditioning effects of ketoro-
lac, as the subjects’s overall pain tolerance decreased. The study 
proves that analgesic placebo responses seem to be primarily 
mediated by expectations, such as verbally induced expectations. 
The study of the placebo phenomenon has important implica-
tions on non-placebo procedures. The equivalent psychological 
factors that mediate the placebo effect are likely to be effective 
when an individual is given an active substance or undergoes 
an active procedure. Accordingly, a better understanding of 
the psychological mechanisms essential to the placebo effect 
is relevant in order to contribute these psychological factors 
to non-placebo treatments as well. For example, by increasing 
patients’ positive expectancies for the effects of an active drug 
or procedure, it is conceivable that the drug or procedure will 
yield stronger drug effects without the use of stronger doses. 
There are numerous ways that physicians can achieve this: They 
can inform patients about others for whom the treatment 
proved successful, and doctors should update patients on the 
clinical research that portrays the treatment as worthwhile. 
Additionally, physicians should make people aware of the minor 
side effects related with the treatment. Then, when people 
come across any such symptoms in themselves (irrespective 
of whether these symptoms are a result of the active drug), 
they are likely to assume that the drug is working well. This will 
possibly boost their expectations for a positive effect, which will 
thereafter enhance the placebo element of the active treatment. 
Using these strategies, physicians can probably achieve stronger 
drug results without administering alternative stronger drugs or 
greater doses. This would be a safer solution for the patient, as 
he or she will not be exposed to unnecessary strong medica-
tion, and this will also decrease the costs of medical care. (Podd, 
Stewart-Williams 2004)
Neurological Aspects
Placebos have no innate power to elicit given results. Yet, they 
can produce the effects which are anticipated or sought. Placebo 
pills and procedures do not act on the brain to bring about pla-
cebo effects; however, placebos can stimulate expectations and 
CR which impact pain-reducing neural systems. What is respon-
sible for the relation between the psychological mechanisms 
and placebo analgesia?
Neurological Aspects: Opioids
The neurology of placebo was discovered when researchers 
found that placebo analgesia is facilitated by endogenous opi-
oids. They were prompted to make this hypothesis after they 
observed that naloxone, the opioid antagonist, can oppose the 
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effects of placebo analgesia (Levine et. al, 1978). Since then, fur-
ther studies have emphasized that finding. Researchers exam-
ined the mechanisms fundamental to the activation of endog-
enous opioids in placebo analgesia (Benedetti, Amanzio 1999). 
Once a day, for five days, ischemic arm pain was induced into 
229 participants. The subjects were divided into twelve groups, 
each treated differently. Each group received a combination of 
two or more of these 
treatments throughout the five-day-experiment duration: the 
opioid agonist morphine hydrochloride, the non-opioid ketoro-
lac (nonsteroidal anti-inflammatory drug; NSAID) trometh-
amine, no treatment, an open injection of saline, or open or 
hidden opioid antagonist naloxone. The order of each group’s 
treatment was made so that the treatment can serve as drug 
conditioning, expectation cues, or both. When morphine was 
administered, and when saline was openly injected and was 
believed to be a morphine-like (expectation and or drug con-
ditioning), participants experienced less pain. Any participant 
who received naloxone after morphine (ketorolac was not 
administered), whether open or hidden and whether used as 
an expectation cue or not, experienced no difference in pain. 
When ketorolac was issued, there was pain relief. Moreover, 
when saline was issued, it mimicked the ketorolac effects. What 
was even more fascinating about the results was that when nal-
oxone was issued after ketorolac, pain was partially diminished. 
This proves that naloxone only somewhat blocks analgesic ef-
fects; therefore, there must be non-opioid factors in addition to 
opioid factors influencing placebo analgesia. The results of the 
experiment prove that the opioid system is surely involved in 
placebo analgesia, yet there are also other aspects sometimes 
involved. 
There is a lack of evidence proving how non-opioid pathways 
serve in placebo analgesia. However, just as ketorolac is a 
NSAID, placebos that mimic ketorolac or other NSAIDs’ ac-
tivity, probably behave like such drugs. They act at peripheral 
and also central places in the spinal cord, hindering the cyc-
lo-oxygenase enzyme that is essential for the transformation 
of arachidonic acid into prostaglandins and thus preventing a 
painful experience. 
Because studies prove the anti-opioid accomplishments of the 
neuropeptide cholecystokinin (CCK), further studies were done 
and demonstrated that the blockade of CCK receptors makes 
the placebo analgesic response possible, thus suggesting that the 
CCK role in placebo analgesia is quite impeding and that the 
opioid system is important in order for placebo analgesia to 
occur. This finding imparts that by irritating the anti-opioid ac-
tion of CCK at the time of a placebo practice, the endogenous 
opioid systems can be activated. (Benedetti, Amanzio 1997) In 
a more recent study, forty participants were divided into four 
groups in order for the effects of CCK type-2 receptors to 
be examined (Benedetti et. al, 2010). Each participant was in-
duced with ischemic arm pain like in previously mentioned ex-
periments, and each group was treated differently. The results 
portrayed that activation of CCK type-2 receptors, which was 
achieved by means of administering the agonist pentagastrin, 
abolished placebo analgesia even after morphine-conditioning 
(placebo treatment) occurred. Evidently, CCK resembles nal-
oxone. Furthermore, this study suggests that the equilibrium 
between CCK elements and opioids is critical in placebo treat-
ment. So, when patients do not respond as predicted to placebo 
treatments, possibly CCK type-2 receptor hyperactivity exists 
in the patient’s body-makeup.
What exactly is the endogenous opioid system? In general, the 
endogenous opioid system is an inborn pain-relieving method. 
It consists of dispersed neurons that produce three opioids: be-
ta-endorphin, the met- and leu-enkephalins, and the dynorphins. 
These opioids behave like neurotransmitters and neuromodu-
lators at three main categories of receptors - mu (µ), Delta (δ), 
and kappa (κ). Once attached to the receptors, they send signals 
which in turn block pain, slow down breathing, and have an over-
all calming effect; therefore, the patient experiences analgesia. 
In order to more fully comprehend how opioids modulate the 
conduction of pain, one needs to understand the pathway by 
which pain is transmitted - beginning from its origin until its place 
of interpretation and perception in the brain.  There are two 
types of first order neurons in which pain is transmitted along: 
In terms of nociceptive pain transmission, acute pain is trans-
mitted mainly by A-delta afferent sensory nerve fibers, while 
chronic pain is transmitted mainly by unmyelinated C sensory 
afferent nerve fibers until it reaches the spinal cord. Because 
these nerve fibers are unmyelinated, chronic pain is transmitted 
slower than acute pain. Nociceptors, free nerve endings which 
are found in numerous visceral and somatic tissues all over the 
body, are stimulated by different sorts of noxious (harmful) 
stimuli - such as chemical, thermal, and mechanical - and once 
stimulated there is a release of leukotrienes, bradykinin, hista-
mine, prostaglandins, potassium ions, and substance P.  These 
substances activate the nociceptors which results in the gener-
ation of an action potential down the first order neurons and 
heading towards the spinal cord.  When the fibers arrive at the 
dorsal gray horn of the spinal cord, they release neurotransmit-
ters - glutamate, substance P, and calcitonin gene related peptide 
- and thus synapse with second order nerve fibers. The released 
neurotransmitters incite the depolarization of the second order 
neuron which crosses over to the opposite side of the spinal 
cord, entering the contralateral spinothalamic tract and from 
there ascends up the spinal cord and ultimately into the brain. 
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Here, pain is modified via descending pathways and this results 
in an individual experiencing pain. 
Now, how do opioids hinder the descending pathways so that 
an individual does not perceive pain? Opioid agonists bind to 
µ -opioid receptors within the midbrain of the brainstem, on 
inhibitory interneurons. The opioid agonist action at these neu-
rons results in a lessening in the inhibitory effects on the nerve 
fibers exiting the periaqueductal gray (PAG). Hence, they lead 
to disinhibition of the descending nerves from the PAG. In turn, 
there is an increase in their motion and in their communication 
to the raphe nuclei. Moreover, there will be a disinhibition of 
neurons in the raphe nuclei. There will be a general stimulation 
of the descending nerve fibers which are descending through 
the lateral funiculus in the spinal cord, and they eventually reach 
the dorsal horn of the spinal cord. As this is the site in which the 
original pain stimulus enters the spinal cord in its ascent to the 
brain, here the nerve fibers influence the activity of the initial 
pain stimulus.
Opioids impede afferent sensory nerve fibers, as well, that are 
ascending the spinal cord traveling towards the brain. Opioids di-
rectly attach to presynaptic mu-opioid receptors and thus cause 
an inhibition of pain transmission through the first order affer-
ent sensory nerve fibers which enter the spinal cord. This leads 
to a lessening in the discharge of substance P that is required 
for the stimulation of second order neurons. Furthermore, opi-
oids can directly attach to postsynaptic mu-opioid receptors on 
different ascending nerve fibers, and this adds to the diminished 
communication to the ventral posterolateral nucleus and con-
sequently to the cerebral cortex. Additionally, opioids can indi-
rectly inhibit second order ascending neurons in the spinal cord; 
they modify the ejection of substance P and serotonin from the 
stimulated descending nerve fibers from the raphe nuclei which 
control endorphin containing neurons inside the dorsal horn. 
The outcome of the impacts of opioids on the nerves found in 
the dorsal horn is the pain transmission inhibition.
As one’s body does not produce enough natural opioids to 
alleviate excruciating or prolonged pain, opioid drugs are man-
ufactured. Comparable to their endogenous complements, opi-
oid drugs - opiates - act at the same receptor sites, producing 
analgesia as well. This wonder is possible, as the drugs mimic the 
endogenous opioids’ chemical makeup. For this reason, patients 
who experience much pain are prescribed with painkillers –as 
they are opiates which mediate analgesia. When a placebo is 
administered, the goal is that the endogenous opioid system 
is activated as a result of the psychological influence on the 
patient’s mind – the individual is convinced he or she received 
an opiate, so his body responds respectively.
Ethics of Placebo Treatment
As the physiology caused by placebo treatment is not conclu-
sive, the placebo effect is not universally recommended. In fact, 
many view placebo treatment as immoral. According to Nikola 
Biller-Andorno (2004) of University of Goettingen, Germany, 
placebo treatment is only permissible when used for thera-
peutic reasons and when no better proven alternative exists. 
Additionally, the patient cannot be deceived, rather the doctor 
must acknowledge the patient’s empowerment and autonomy. 
If the physician fails to abide by these standards, rather than 
practicing ethically he is practicing blunderingly. Because of such 
guidelines, it is difficult to practice placebo treatment on sick 
patients. Therefore, researchers are forced to set up trials in 
order to examine placebo effects.
Ethnic
After much research, it is noticeable that the placebo effect has 
become more effective. DiSalvo elaborated about the placebo 
effect in a 2015 edition of the Forbes magazine. He wrote that 
after reviewing a study of 84 clinical trials which were carried 
out between the years 1990 and 2013, he concluded that the 
placebo effect is getting stronger. However, he adds that this is 
only true of trials in the United States. Possibly because America 
is more advanced than many countries, the ability to conduct 
placebo treatments is more feasible. More importantly, he adds 
that America is the only country aside from New Zealand 
that allows drug companies to sell their products directly to 
consumers. This is blatant when one watches TV and sees the 
numerous drug commercials. The advertising in itself can con-
tribute towards the placebo effect by creating expectation cues.
Conclusion
After examining the articles and experiments regarding pla-
cebo treatments and effects, it is apparent that while placebo 
treatment definitely has psychological influence on patients, the 
neurological influence is unclear. Many are skeptical of placebo 
effect all together. They argue that possibly the percentage of 
patients that report improvement would regardless have im-
provement – that is to say, often pain reduces over time so even 
without a placebo treatment one can be somewhat relieved 
from pain. However, in many trials, there are ‘natural history’ 
groups which are used to compare their pain tolerance to the 
placebo treated group’s pain tolerance. And these studies have 
proven that the placebo treated group’s pain tolerance was bet-
ter than the non-placebo treated group’s tolerance. This topic 
is fascinating as it proves the power of the mind over matter. 
Placebo management can trigger mechanisms that are equiv-
alent to those triggered by drugs, which points out a parallel 
between psychological and pharmaceutical effects. With further 
research, placebo effect may become completely acceptable and 
instead of administering drugs which often have harmful side 
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effects or which are sometimes rejected by patients, placebo 
treatments will serve as alternatives.
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